Glenn Sblendorio, Iveric Bio CEO

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Two years ago, as Iver­ic Bio went through late-stage stud­ies of its main ex­per­i­men­tal drug, it be­gan at­tract­ing in­ter­est from po­ten­tial buy­ers. Five com­pa­nies end­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.